Novartis Ag (NVSEF) Capital Expenditures Growth (5y) (2014 - 2026)

Novartis Ag (NVSEF) Capital Expenditures Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag - - -

Historic Data

Download Data
DateValue
Mar 31, 2026 -7.06%
Dec 31, 2025 -3.17%
Sep 30, 2025 -4.88%
Jun 30, 2025 -6.82%
Mar 31, 2025 -1.40%
Dec 31, 2024 -3.89%
Sep 30, 2024 2.10%
Jun 30, 2024 1.40%
Mar 31, 2024 4.25%
Dec 31, 2023 1.77%
Sep 30, 2023 2.42%
Jun 30, 2023 2.62%
Mar 31, 2023 8.22%
Dec 31, 2022 13.67%
Sep 30, 2022 10.37%
Jun 30, 2022 4.99%
Mar 31, 2022 5.66%
Dec 31, 2021 4.73%
Sep 30, 2021 4.55%
Jun 30, 2021 6.45%